Lynn Butler

SIRENADE Pharmaceuticals AG provides preclinical research and development services. Core clinical and preclinical competencies are an articulated pipeline of projects in CNS and oncology. The firm focuses projects that target Alzheimer's disease, Parkinson disease and migraine. Out of three preclinical projects, one targets Alzheimer's disease and two early stage projects are targeting solid tumors and other cancers with unmet medical need. The company uses a proprietary integrated research and development platform that addresses nucleotide-binding targets and kinases. The company was founded in 2004 and is headquartered in Munich, Germany.